Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective
- 1 May 2002
- journal article
- editorial
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 294 (1) , 1-4
- https://doi.org/10.1016/s0006-291x(02)00359-5
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1Biochemical and Biophysical Research Communications, 2002
- Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea TreatmentDiabetes Care, 2001
- The Glucagon-Like PeptidesEndocrine Reviews, 1999
- Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDMDiabetes, 1996
- Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patientsDiabetologia, 1993
- Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes MellitusNew England Journal of Medicine, 1992
- Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic SubjectsDiabetes Care, 1992
- Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.Journal of Clinical Investigation, 1987
- Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutFEBS Letters, 1987
- Hamster preproglucagon contains the sequence of glucagon and two related peptidesNature, 1983